FY2025 EPS Estimates for Moderna Decreased by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for shares of Moderna in a research note issued to investors on Sunday, November 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($9.90) per share for the year, down from their previous estimate of ($9.89). The consensus estimate for Moderna’s current full-year earnings is ($9.43) per share.

MRNA has been the subject of a number of other research reports. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Piper Sandler reissued an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a report on Monday. JPMorgan Chase & Co. decreased their price target on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday, November 4th. Finally, The Goldman Sachs Group dropped their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Stock Down 5.6 %

Shares of MRNA opened at $37.29 on Wednesday. The firm has a market cap of $14.35 billion, a P/E ratio of -6.41 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a 52 week low of $35.80 and a 52 week high of $170.47. The firm’s 50-day simple moving average is $57.82 and its 200 day simple moving average is $96.07.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm posted ($1.39) EPS. The company’s quarterly revenue was up 3.8% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Intrinsic Value Partners LLC boosted its stake in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after buying an additional 69,313 shares during the period. Profund Advisors LLC grew its position in shares of Moderna by 20.9% in the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after buying an additional 9,719 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Moderna by 4.2% in the third quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock valued at $25,359,000 after buying an additional 15,218 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This trade represents a 13.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 2,930 shares of company stock valued at $217,170 over the last ninety days. 15.20% of the stock is owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.